RxDoctor Payments Data

Nicole Puterbaugh

Family · Cincinnati, OHNPI 1407017270

Payments from drug & device makers

$4,146in general payments, 2019–2025

Across 222 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$867
  • Novo Nordisk$610
  • Lilly USA, LLC$549
  • Pfizer$211
  • Mayne Pharma Commercial LLC$113
  • plus $708 from 20 others

What the payments were for

  • Food & beverage$4,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,146 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$30,599
Medicare patients
126
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$39,298
EliquisApixaban21$25,049
JardianceEmpagliflozin18$16,933
MounjaroTirzepatide13$13,412
Breo ElliptaFluticasone/Vilanterol13$5,970
BelsomraSuvorexant12$5,419
Arnuity ElliptaFluticasone Furoate13$5,116
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,395
Rosuvastatin Calcium183$2,784
Atorvastatin Calcium307$2,354
Celecoxib34$2,291
Bupropion XlBupropion Hcl47$1,558
SynthroidLevothyroxine Sodium30$1,482
Levothyroxine Sodium149$1,428
Albuterol Sulfate HfaAlbuterol Sulfate77$1,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$867$39,29834 claims
PfizerEliquis$211$25,04921 claims
Boehringer IngelheimJardiance$31$16,93318 claims
Lilly USA, LLCMounjaro$549$13,41213 claims
GSKBreo Ellipta, Arnuity Ellipta$52$11,08626 claims
MerckBelsomra$31$5,41912 claims
AbbVieSynthroid$1,087$1,48230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →